StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Gilead Sciences (GILD) Needs M&A to Fill the Gap Following HCV Miss - BMO Capital
April 29, 2016 7:40 AM
BMO Capital analyst M. Ian Somaiya lowered his price target on Gilead Sciences (NASDAQ: GILD) to $97.00 (from $102.00) following ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Rumors
Next Articles
Gilead Sciences (GILD) PT Lowered to $118 at UBS
April 29, 2016 8:27 AM
Baird Maintains Bullish View on Gilead Sciences (GILD) Despite Top-Line Miss on U.S. Hep C Sales
April 29, 2016 7:30 AM
Maxim Group Downgrades Gilead Sciences (GILD) to Hold
April 29, 2016 7:06 AM
Gilead Sciences (GILD) PT Trimmed to $123 at Leerink Partners
April 29, 2016 6:50 AM
Gilead Sciences (GILD) Raises Quarterly Dividend 9.3% to $0.47; 1.9% Yield
April 28, 2016 4:07 PM
Gilead Sciences Announces Second Quarter 2016 Dividend
April 28, 2016 4:06 PM
Gilead Sciences (GILD) Misses Q1 EPS by 10c
April 28, 2016 4:05 PM
Gilead Sciences Announces First Quarter 2016 Financial Results
April 28, 2016 4:02 PM
